Sanara MedTech Inc. (SMTI) Q3 2025 10-Q Quarterly Report
Filed: Nov 12, 2025Period ending Sep 30, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR Sanara MedTech Inc. (SMTI) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Sanara MedTech Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New financial risk: CRG Term Loan amendment allows up to two additional borrowings totaling $12.25 million by Dec 31, 2025, increasing debt capacity
- • Most materially updated operational risk: Discontinuation of THP segment following persistent losses and failed investor interest, segment impairment of $31.2 million Q3 2025
Sanara MedTech Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$26M
▲ +21.4% YoY▲ +1.8% QoQ
Net Income
-$30M
▼ -964.2% YoY▼ -1409.7% QoQ
Gross Margin
92.9%
▲ +207bp YoY▲ +38bp QoQ
Operating Margin
31.8%
▲ +4068bp YoY▲ +3192bp QoQ
Net Margin
-115.6%
▼ -10241bp YoY▼ -10780bp QoQ
ROE
-494.6%
Total Assets
$71M
EPS (Diluted)
$-3.40
▼ -900.0% YoY▼ -1378.3% QoQ
Operating Cash Flow
$2M
▲ +6.1% YoY▼ -18.3% QoQ
Source: XBRL data from Sanara MedTech Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Sanara MedTech Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.